Pro-resolving lipid mediators (SPMs) and their actions in regulating miRNA in novel resolution circuits in inflammation

Frontiers in Immunology

Volumn 3, Issue OCT, 2012, Pages

  Recchiuti, Antonio ^a,b   Serhan, Charles N ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b UNIVERSITY OF CHIETI   (Italy)

Author keywords

Lipoxin; n 3 PUFA; Protectin; Resolution; Resolvin

Indexed keywords

EID: 84874195947     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2012.00298     Document Type: Review

References (163)

1. Abbas, A. K., Lichtman, A. H., and Pillai, S. (2011). Cellular and Molecular Immunology, 7th Edn. Philadelphia: Elsevier Saunders.
2. Alam, M. M., and O'Neill, L. A. (2011). MicroRNAs and the resolution phase of inflammation in macrophages. Eur. J. Immunol. 41, 2482-2485.
3. Aoki, H., Hisada, T., Ishizuka, T., Utsugi, M., Kawata, T., Shimizu, Y., Okajima, F., Dobashi, K., and Mori, M. (2008). Resolvin E1 dampens airway inflammation and hyperresponsiveness in a murine model of asthma. Biochem. Biophys. Res. Commun. 367, 509-515.
4. Aoki, H., Hisada, T., Ishizuka, T., Utsugi, M., Ono, A., Koga, Y., Sunaga, N., Nakakura, T., Okajima, F., Dobashi, K., and Mori, M. (2010). Protective effect of resolvin E1 on the development of asthmatic airway inflammation. Biochem. Biophys. Res. Commun. 400, 128-133.
5. Ariel, A., Fredman, G., Sun, Y.-P., Kantarci, A., Van Dyke, T. E., Luster, A. D., and Serhan, C. N. (2006). Apoptotic neutrophils and T cells sequester chemokines during immune response resolution through modulation of CCR5 expression. Nat. Immunol. 7, 1209-1216.
6. Ariel, A., Li, P.-L., Wang, W., Tang, W.X., Fredman, G., Hong, S., Gotlinger, K. H., and Serhan, C. N. (2005). The docosatriene protectin D1 is produced by TH2 skewing and promotes human T cell apoptosis via lipid raft clustering. J. Biol. Chem. 280, 43079-43086.
7. Arita, M., Bianchini, F., Aliberti, J., Sher, A., Chiang, N., Hong, S., Yang, R., Petasis, N. A., and Serhan, C. N. (2005a). Stereochemical assignment, antiinflammatory properties, and receptor for the omega-3 lipid mediator resolvin E1. J. Exp. Med. 201, 713-722.
8. Arita, M., Yoshida, M., Hong, S., Tjonahen, E., Glickman, J. N., Petasis, N. A., Blumberg, R. S., and Serhan, C. N. (2005b). Resolvin E1, an endogenous lipid mediator derived from omega-3 eicosapentaenoic acid, protects against 2,4,6-trinitrobenzene sulfonic acidinduced colitis. Proc. Natl. Acad. Sci. U.S.A. 102, 7671-7676.
9. Arita, M., Ohira, T., Sun, Y.-P., Elangovan, S., Chiang, N., and Serhan, C. N. (2007). Resolvin E1 selectively interacts with leukotriene B4 receptor BLT1 and ChemR23 to regulate inflammation. J. Immunol. 178, 3912-3917.
10. Bandeira-Melo, C., Serra, M. F., Diaz, B. L., Cordeiro, R. S., Silva, P. M., Lenzi, H. L., Bakhle, Y. S., Serhan, C. N., and Martins, M. A. (2000). Cyclooxygenase2-derived prostaglandin E2 and lipoxin A4 accelerate resolution of allergic edema in Angiostrongylus costaricensis-infected rats: relationship with concurrent eosinophilia. J. Immunol. 164, 1029-1036.
11. Bang, S.,Yoo, S.,Yang, T. J., Cho, H., and Hwang,S. (2012). 17(R)-resolvin D1 specifically inhibits TRPV3 leading to peripheral antinociception. Br. J. Pharmacol. 165, 683-692.
12. Bang, S., Yoo, S., Yang, T. J., Cho, H., Kim,Y. G., and Hwang, S. W. (2010). Resolvin D1 attenuates activation of sensory transient receptor potential channels leading to multiple antinociception. Br. J. Pharmacol. 161, 707-720.
13. Bannenberg, G., and Serhan, C. N. (2010). Specialized pro-resolving lipid mediators in the inflammatory response: an update. Biochim. Biophys. Acta 1801, 1260-1273.
14. Bannenberg, G. L., Chiang, N., Ariel, A., Arita, M., Tjonahen, E., Gotlinger, K. H., Hong, S., and Serhan, C. N. (2005). Molecular circuits of resolution: formation and actions of resolvins and protectins. J. Immunol. 174, 4345-4355.
15. Bartel, D. P. (2009). MicroRNAs: target recognition and regulatory functions. Cell 136, 215-233.
16. Bazan, N. G. (2007). Homeostatic regulation of photoreceptor cell integrity: significance of the potent mediator neuroprotectin D1 biosynthesized from docosahexaenoic acid: the Proctor Lecture. Invest. Ophthalmol. Vis. Sci. 48, 4866-4881; biography 4864-4865.
17. Bento, A. F., Claudino, R. F., Dutra, R. C., Marcon, R., and Calixto, J. B. (2011). Omega-3 fatty acidderived mediators 17(R)-hydroxy docosahexaenoic acid, aspirintriggered resolvin D1 and resolvin D2 prevent experimental colitis in mice. J. Immunol. 187, 1957-1969.
18. Brink, C., Dahlen, S. E., Drazen, J., Evans, J. F., Hay, D. W., Nicosia, S., Serhan, C. N., Shimizu, T., and Yokomizo, T. (2003). International Union of Pharmacology XXXVII. Nomenclature for leukotriene and lipoxin receptors. Pharmacol. Rev. 55, 195-227.
19. Burr, G. O., and Burr, M. M. (1929). A new deficiency disease produced by the rigid exclusion of fat from the diet. J. Biol. Chem. 82, 345-367.
20. Calder, P. C. (2009). Polyunsaturated fatty acids and inflammatory processes: New twists in an old tale. Biochimie 91, 791-795.
21. Campbell, E. L., MacManus, C. F., Kominsky, D. J., Keely, S., Glover, L. E., Bowers, B. E., Scully, M., Bruyninckx,W. J., and Colgan, S. P. (2010). Resolvin E1-induced intestinal alkaline phosphatase promotes resolution of inflammation through LPS detoxification. Proc. Natl. Acad. Sci. U.S.A. 107, 14298-14303.
22. Chan, M. M., and Moore, A. R. (2010). Resolution of inflammation in murine autoimmune arthritis is disrupted by cyclooxygenase-2 inhibition and restored by prostaglandin E2-mediated lipoxin A4 production. J. Immunol. 184, 6418-6426.
23. Chen, Y., Hao, H., He, S., Cai, L., Li, Y., Hu, S., Ye, D., Hoidal, J., Wu, P., and Chen, X. (2010). Lipoxin A4 and its analogue suppress the tumor growth of transplanted H22 in mice: the role of antiangiogenesis. Mol. Cancer Ther. 9, 2164-2174.
24. Chiang, N., Bermudez, E. A., Ridker, P. M., Hurwitz, S., and Serhan, C. N. (2004). Aspirin triggers antiinflammatory 15-epi-lipoxin A4 and inhibits thromboxane in a randomized human trial. Proc. Natl. Acad. Sci. U.S.A. 101, 15178-15183.
25. Chiang, N., Fredman, G., Bäckhed, F., Oh, S. F., Vickery, T. W., Schmidt, B. A., and Serhan, C. N. (2012). Infection regulates proresolving mediators that lower antibiotic requirements. Nature 484, 524-528.
26. Chiang, N., Gronert, K., Clish, C. B., O'Brien, J. A., Freeman, M. W., and Serhan, C. N. (1999). Leukotriene B4 receptor transgenic mice reveal novel protective roles for lipoxins and aspirin-triggered lipoxins in reperfusion. J. Clin. Invest. 104, 309-316.
27. Chiang, N., Serhan, C. N., Dahlen, S. E., Drazen, J. M., Hay, D. W., Rovati, G. E., Shimizu, T., Yokomizo, T., and Brink, C. (2006). The lipoxin receptor ALX: potent ligand-specific and stereoselective actions in vivo. Pharmacol. Rev. 58, 463-487.
28. Chiang,N.,Takano,T.,Arita,M.,Watanabe, S., and Serhan, C. N. (2003). A novel rat lipoxin A4 receptor that is conserved in structure and function. Br. J. Pharmacol. 139, 89-98.
29. Claria, J., and Serhan, C. N. (1995). Aspirin triggers previously undescribed bioactive eicosanoids by human endothelial cell-leukocyte interactions. Proc. Natl. Acad. Sci. U.S.A. 92, 9475-9479.
30. Clish, C. B., O'Brien, J. A., Gronert, K., Stahl, G. L., Petasis, N. A., and Serhan,C. N.(1999).Local and systemic delivery of a stable aspirin-triggered lipoxin prevents neutrophil recruitment in vivo. Proc. Natl. Acad. Sci. U.S.A. 96, 8247-8252.
31. Connor, K. M., Sangiovanni, J. P., Lofqvist, C., Aderman, C. M., Chen, J., Higuchi, A., Hong, S., Pravda, E. A., Majchrzak, S., Carper, D., Hellstrom, A., Kang, J. X., Chew, E. Y., Salem, N., Serhan, C. N., and Smith, L. E. H. (2007). Increased dietary intake of omega-3-polyunsaturated fatty acids reduces pathological retinal angiogenesis. Nat. Med. 13, 868-873.
32. Conte, F. P., Menezes-De-Lima, O., Verri, W. A., Cunha, F. Q., Penido, C., and Henriques, M. G. (2010). Lipoxin A(4) attenuates zymosaninduced arthritis by modulating endothelin-1 and its effects. Br. J. Pharmacol. 161, 911-924.
33. Dalli, J., Norling, L. V., Renshaw, D., Cooper, D., Leung, K. Y., and Perretti, M. (2008). Annexin 1 mediates the rapid anti-inflammatory effects of neutrophil-derived microparticles. Blood 112, 2512-2519.
34. De Caterina, R. (2011). n-3 fatty acids in cardiovascular disease. N. Engl. J. Med. 364, 2439-2450.
35. Devchand, P. R., Arita, M., Hong, S., Bannenberg, G., Moussignac, R. L., Gronert, K., and Serhan, C. N. (2003). Human ALX receptor regulates neutrophil recruitment in transgenic mice: roles in inflammation and host defense. FASEB J. 17, 652-659.
36. Devchand, P. R., Schmidt, B. A., Primo, V. C., Zhang, Q.-Y., Arnaout, M. A., Serhan, C. N., and Nikolic, B. (2005). A synthetic eicosanoid LXmimetic unravels host-donor interactions in allogeneic BMT-induced GvHD to reveal an early protective role for host neutrophils. FASEB J. 19, 203-210.
37. Dona, M., Fredman, G., Schwab, J. M., Chiang, N., Arita, M., Goodarzi, A., Cheng, G., Von Andrian, U. H., and Serhan, C. N. (2008). Resolvin E1, an EPA-derived mediator in whole blood, selectively counterregulates leukocytes and platelets. Blood 112, 848-855.
38. Duffield, J. S., Hong, S., Vaidya, V. S., Lu, Y., Fredman, G., Serhan, C. N., and Bonventre, J. V. (2006). Resolvin D series and protectin D1 mitigate acute kidney injury. J. Immunol. 177, 5902-5911.
39. Dufton, N., Hannon, R., Brancaleone, V., Dalli, J., Patel, H. B., Gray, M., D'Acquisto, F., Buckingham, J. C., Perretti, M., and Flower, R. J. (2010). Anti-inflammatory role of the murine formyl-peptide receptor 2: ligand-specific effects on leukocyte responses and experimental inflammation. J. Immunol. 184, 2611-2619.
40. Edenius, C., Kumlin, M., Bjork, T., Anggard, A., and Lindgren, J. A. (1990). Lipoxin formation in human nasal polyps and bronchial tissue. FEBS Lett. 272, 25-28.
41. Fierro, I. M., Kutok, J. L., and Serhan, C. N. (2002). Novel lipid mediator regulators of endothelial cell proliferation and migration: aspirin-triggered-15R-lipoxin A(4) and lipoxin A(4). J. Pharmacol. Exp. Ther. 300, 385-392.
42. Fiore, S., Brezinski, M. E., Sheppard, K. A., and Serhan, C. N. (1991). The lipoxin biosynthetic circuit and their actions with human neutrophils. Adv. Exp. Med. Biol. 314, 109-132.
43. Fiore, S., Maddox, J. F., Perez, H. D., and Serhan, C. N. (1994). Identification of a human cDNA encoding a functional high affinity lipoxin A4 receptor. J. Exp. Med. 180, 253-260.
44. Fiore, S., Ryeom, S. W., Weller, P. F., and Serhan, C. N. (1992). Lipoxin recognition sites. Specific binding of labeled lipoxin A4 with human neutrophils. J. Biol. Chem. 267, 16168-16176.
45. Flower, R. J. (2006). Prostaglandins, bioassay and inflammation. Br. J. Pharmacol. 147(Suppl. 1), S182- S192.
46. Fredman, G., Oh, S. F., Ayilavarapu, S., Hasturk, H., Serhan, C. N., and Van Dyke, T. E. (2011). Impaired phagocytosis in localized aggressive periodontitis: rescue by resolvin E1. PLoS ONE 6, e24422. doi:10.1371/journal.pone.0024422
47. Fredman, G., and Serhan, C. N. (2011). Specialized pro-resolving mediator targets for RvE1 and RvD1 in peripheral blood and mechanisms of resolution. Biochem. J. 437,185-197.
48. Freire-de-Lima, C. G., Xiao, Y. Q., Gardai, S. J., Bratton, D. L., Schiemann, W. P., and Henson, P. M. (2006). Apoptotic cells, through transforming growth factor-beta, coordinately induce anti-inflammatory and suppress pro-inflammatory eicosanoid and NO synthesis in murine macrophages. J. Biol. Chem. 281, 38376-38384.
49. Gasser, O., and Schifferli, J. A. (2004). Activated polymorphonuclear neutrophils disseminate antiinflammatory microparticles by ectocytosis. Blood 104, 2543-2548.
50. Gewirtz, A. T., Neish, A. S., and Madara, J. L. (2002). Mechanisms of active intestinal inflammation and potential down-regulation via lipoxins. Adv. Exp. Med. Biol. 507, 229-236.
51. Gilroy, D. W., Colville-Nash, P. R., Willis, D., Chivers, J., Paul-Clark, M. J., and Willoughby, D. A. (1999). Inducible cyclooxygenase may have anti-inflammatory properties. Nat. Med. 5, 698-701.
52. GISSI-Prevenzione Investigators. (1999). Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSIPrevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico. Lancet 354, 447-455.
53. Godson, C., Mitchell, S., Harvey, K., Petasis, N. A., Hogg, N., and Brady, H. R. (2000). Cutting edge: lipoxins rapidly stimulate nonphlogistic phagocytosis of apoptotic neutrophils by monocytederived macrophages. J. Immunol. 164, 1663-1667.
54. Gonzalez-Periz, A., Horrillo, R., Ferre, N., Gronert, K., Dong, B., MoranSalvador, E., Titos, E., MartinezClemente, M., Lopez-Parra, M., Arroyo, V., and Claria, J. (2009). Obesityinduced insulin resistance and hepatic steatosis are alleviated by omega-3 fatty acids: a role for resolvins and protectins. FASEB J. 23, 1946-1957.
55. Gordon, S. (2007). The macrophage: past, present and future. Eur. J. Immunol. 37(Suppl. 1), S9-S17.
56. Gronert, K., Gewirtz, A., Madara, J. L., and Serhan, C. N. (1998). Identification of a human enterocyte lipoxin A4 receptor that is regulated by interleukin (IL)-13 and interferon gamma and inhibits tumor necrosis factor alpha-induced IL-8 release. J. Exp. Med. 187, 1285-1294.
57. Gronert, K., Maheshwari, N., Khan, N., Hassan,I. R.,Dunn,M.,and Laniado Schwartzman, M. (2005). A role for the mouse 12/15-lipoxygenase pathway in promoting epithelial wound healing and host defense. J. Biol. Chem. 280, 15267-15278.
58. Gronert, K., Martinsson-Niskanen, T., Ravasi, S., Chiang, N., and Serhan, C. N. (2001). Selectivity of recombinant human leukotriene D(4), leukotriene B(4), and lipoxin A(4) receptors with aspirin-triggered 15epi-LXA(4) and regulation of vascular and inflammatory responses.Am. J. Pathol. 158, 3-9.
59. Haas-Stapleton, E. J., Lu, Y., Hong, S., Arita, M., Favoreto, S., Nigam, S., Serhan, C. N., and Agabian, N. (2007). Candida albicans modulates host defense by biosynthesizing the pro-resolving mediator resolvin E1. PLoS ONE 2, e1316. doi:10.1371/journal.pone.0001316
60. Hasturk, H., Kantarci, A., GoguetSurmenian, E., Blackwood, A., Andry, C., Serhan, C. N., and Van Dyke, T. E. (2007). Resolvin E1 regulates inflammation at the cellular and tissue level and restores tissue homeostasis in vivo. J. Immunol. 179, 7021-7029.
61. Hasturk, H., Kantarci, A., Ohira, T., Arita, M., Ebrahimi, N., Chiang, N., Petasis, N. A., Levy, B. D., Serhan, C. N., and Van Dyke, T. E. (2006). RvE1 protects from local inflammation and osteoclastmediated bone destruction in periodontitis. FASEB J. 20, 401-403.
62. Haworth, O., Cernadas, M., Yang, R., Serhan,C. N.,and Levy,B. D. (2008). Resolvin E1 regulates interleukin 23, interferon-gamma and lipoxin A4 to promote the resolution of allergic airway inflammation. Nat. Immunol. 9, 873-879.
63. Hellmann, J., Tang,Y., Kosuri, M., Bhatnagar, A., and Spite, M. (2011). Resolvin D1 decreases adipose tissue macrophage accumulation and imiproves insulin sensitivity in obese-diabetic mice. FASEB J. 25, 2399-2407.
64. Hong, S., Gronert, K., Devchand, P. R., Moussignac, R. L., and Serhan, C. N. (2003). Novel docosatrienes and 17S-resolvins generated from docosahexaenoic acid in murine brain, human blood, and glial cells. Autacoids in anti-inflammation. J. Biol. Chem. 278, 14677-14687.
65. Hong, S., Lu, Y., Yang, R., Gotlinger, K. H., Petasis, N. A., and Serhan, C. N. (2007). Resolvin D1, protectin D1, and related docosahexaenoic acidderived products: analysis via electrospray/low energy tandem mass spectrometry based on spectra and fragmentation mechanisms. J. Am. Soc. Mass Spectrom. 18, 128-144.
66. Hong, S., Porter, T. F., Lu, Y., Oh, S. F., Pillai, P. S., and Serhan, C. N. (2008). Resolvin E1 metabolome in local inactivation during inflammation-resolution. J. Immunol. 180, 3512-3519.
67. Honn, K. V., Grossi, I. M., Diglio, C. A., Wojtukiewicz, M., and Taylor, J. D. (1989). Enhanced tumor cell adhesion to the subendothelial matrix resulting from 12(S)-HETE-induced endothelial cell retraction. FASEB J. 3, 2285-2293.
68. Huang, L., Wang, C.-F., Serhan, C. N., and Strichartz, G. (2011). Enduring prevention and transient reduction of post-operative pain by intrathecal resolvin D1. Pain 152, 557-565.
69. Iigo, M., Nakagawa, T., Ishikawa, C., Iwahori, Y., Asamoto, M., Yazawa, K., Araki, E., and Tsuda, H. (1997). Inhibitory effects of docosahexaenoic acid on colon carcinoma 26 metastasis to the lung. Br. J. Cancer 75, 650-655.
70. Iorio, M. V., and Croce, C. M. (2009). MicroRNAs in cancer: small molecules with a huge impact. J. Clin. Oncol. 27, 5848-5856.
71. Ishida, T., Yoshida, M., Arita, M., Nishitani, Y., Nishiumi, S., Masuda, A., Mizuno, S., Takagawa, T., Morita, Y., Kutsumi, H., Inokuchi, H., Serhan, C. N., Blumberg, R. S., and Azuma, T. (2010). Resolvin E1, an endogenous lipid derived from eicosapentaenoic acid, prevents dextran sulfate sodium-induced colitis. Inflamm. Bowel Dis. 16, 87-95.
72. Jin, Y., Arita, M., Zhang, Q., Saban, D. R., Chauhan, S. K., Chiang, N., Serhan, C. N., and Dana, R. (2009). Anti-angiogenesis effect of the novel anti-inflammatory and pro-resolving lipidmediators. Invest. Ophthalmol. Vis. Sci. 50, 4743-4752.
73. Karp, C. L., Flick, L. M., Park, K. W., Softic, S., Greer, T. M., Keledjian, R., Yang, R., Uddin, J., Guggino, W. B., Atabani, S. F., Belkaid, Y., Xu, Y., Whitsett, J. A., Accurso, F. J., Wills-Karp, M., and Petasis, N. A. (2004). Defective lipoxin-mediated anti-inflammatory activity in the cystic fibrosis airway. Nat. Immunol. 5, 388-392.
74. Kasuga, K., Yang, R., Porter, T. F., Agrawal,N.,Petasis,N. A.,Irimia,D., Toner, M., and Serhan, C. N. (2008). Rapid appearance of resolvin precursors in inflammatory exudates: novel mechanisms in resolution. J. Immunol. 181, 8677-8687.
75. Keyes, K. T., Ye, Y., Lin, Y., Zhang, C., Perez-Polo, J. R., Gjorstrup, P., and Birnbaum, Y. (2010). Resolvin E1 protects the rat heart against reperfusion injury. Am. J. Physiol. Heart Circ. Physiol. 299, H153-H164.
76. Krishnamoorthy, S., Recchiuti, A., Chiang, N., Fredman, G., and Serhan, C. N. (2012). Resolvin D1 receptor stereoselectivity and regulation of inflammation and pro-resolving microRNAs. Am. J. Pathol. 180, 2018-2027.
77. Krishnamoorthy, S., Recchiuti, A., Chiang, N., Yacoubian, S., Lee, C.-H., Yang, R., Petasis, N. A., and Serhan, C. N. (2010). Resolvin D1 binds human phagocytes with evidence for pro-resolving receptors. Proc. Natl. Acad. Sci. U.S.A. 107, 1660-1665.
78. Kunkel, S. L., Ogawa, H., Conran, P. B., Ward, P. A., and Zurier, R. B. (1981). Suppression of acute and chronic inflammation by orally administered prostaglandins. Arthritis Rheum. 24, 1151-1158.
79. Lawrence, T., Gilroy, D. W., ColvilleNash, P. R., and Willoughby, D. A. (2001). Possible new role for NFkappaB in the resolution of inflammation. Nat. Med. 7, 1291-1297.
80. Leitch, A. E., Lucas, C. D., Marwick, J. A., Duffin, R., Haslett, C., and Rossi, A. G. (2012). Cyclindependent kinases 7 and 9 specifically regulate neutrophil transcription and their inhibition drives apoptosis to promote resolution of inflammation. Cell Death Differ. doi: 10.1038/cdd.2012.80. [Epub ahead of print].
81. Levy, B. D., Clish, C. B., Schmidt, B., Gronert, K., and Serhan, C. N. (2001). Lipid mediator class switching during acute inflammation: signals in resolution. Nat. Immunol. 2, 612-619.
82. Levy, B. D., De Sanctis, G. T., Devchand, P. R., Kim, E., Ackerman, K., Schmidt,B.A.,Szczeklik,W.,Drazen, J. M., and Serhan, C. N. (2002). Multi-pronged inhibition of airway hyper-responsiveness and inflammation by lipoxin A(4). Nat. Med. 8, 1018-1023.
83. Levy, B. D., Kohli, P., Gotlinger, K., Haworth, O., Hong, S., Kazani, S., Israel, E., Haley, K. J., and Serhan, C. N. (2007). Protectin D1 is generated in asthma and dampens airway inflammation and hyperresponsiveness. J. Immunol. 178, 496-502.
84. Levy, B. D., Romano, M., Chapman, H. A., Reilly, J. J., Drazen, J., and Serhan, C. N. (1993). Human alveolar macrophages have 15-lipoxygenase and generate 15(S)-hydroxy-5,8,11cis-13-trans-eicosatetraenoic acid and lipoxins. J. Clin. Invest. 92, 1572-1579.
85. Levy, B. D., Zhang, Q. Y., Bonnans, C., Primo, V., Reilly, J. J., Perkins, D. L., Liang, Y., Arnaout, M. A., Nikolic, B., and Serhan, C. N. (2011). The endogenous proresolving mediators lipoxin A4 and resolvin E1 preserve organ function in allograft rejection. Prostaglandins Leukot. Essent. Fatty Acids 84, 43-50.
86. Li, N., He, J., Schwartz, C. E., Gjorstrup, P., and Bazan, H. E. P. (2010). Resolvin E1 improves tear production and decreases inflammation in a dry eye mouse model. J. Ocul. Pharmacol. Ther. 26, 431-439.
87. Lima-Garcia, J., Dutra, R., Da Silva, K., Motta, E., Campos, M., and Calixto, J. (2011). The precursor of resolvin D series and aspirin-triggered resolvin D1 display anti-hyperalgesic properties in adjuvant-induced arthritis in rats. Br. J. Pharmacol. 164, 278-293.
88. Lukiw, W. J., and Bazan, N. G. (2008). Docosahexaenoic acid and the aging brain. J. Nutr. 138, 2510-2514.
89. Maddox, J. F., Hachicha, M., Takano, T., Petasis, N. A., Fokin, V. V., and Serhan, C. N. (1997). Lipoxin A4 stable analogs are potent mimetics that stimulate human monocytes and THP-1 cells via a G-proteinlinked lipoxin A4 receptor. J. Biol. Chem. 272, 6972-6978.
90. Maderna, P., Cottell, D. C., Berlasconi, G., Petasis, N. A., Brady, H. R., and Godson, C. (2002). Lipoxins induce actin reorganization in monocytes and macrophages but not in neutrophils: differential involvement of rho GTPases. Am. J. Pathol. 160, 2275-2283.
91. Majno, G. (1991). The Healing Hand Man and Wound in the Ancient World. Cambridge: Harvard University Press.
92. Majno,G.,and Joris,I. (1996). Cells,Tissues and Disease: Principles of General Pathology. Cambridge:Blackwell Science.
93. Marcheselli, V. L., Hong, S., Lukiw, W. J., Tian, X. H., Gronert, K., Musto, A., Hardy, M., Gimenez, J. M., Chiang, N., Serhan, C. N., and Bazan, N. G. (2003). Novel docosanoids inhibit brain ischemia-reperfusionmediated leukocyte infiltration and pro-inflammatory gene expression. J. Biol. Chem. 278, 43807-43817.
94. Marcheselli, V. L., Mukherjee, P. K., Arita, M., Hong, S., Antony, R., Sheets, K., Petasis, N., Serhan, C. N., and Bazan, N. G. (2010). Neuroprotectin D1/protectin D1 stereoselective and specific binding with human retinal pigment epithelial cells and neutrophils. Prostaglandins Leukot. Essent. Fatty Acids 82, 27-34.
95. Morris, T., Stables, M., Colville-Nash, P., Newson, J., Bellingan, G., De Souza, P. M., and Gilroy, D. W. (2010). Dichotomy in duration and severity of acute inflammatory responses in humans arising from differentially expressed proresolution pathways. Proc. Natl. Acad. Sci. U.S.A. 107, 8842-8847.
96. Morris, T., Stables, M., Hobbs, A., De Souza, P., Colville-Nash, P., Warner, T., Newson, J., Bellingan, G., and Gilroy, D. W. (2009). Effects of lowdose aspirin on acute inflammatory responses in humans. J. Immunol. 183, 2089-2096.
97. Mukherjee, P. K., Marcheselli, V. L., Serhan, C. N., and Bazan, N. G. (2004). Neuroprotectin D1: a docosahexaenoic acid-derived docosatriene protects human retinal pigment epithelial cells from oxidative stress. Proc. Natl. Acad. Sci. U.S.A. 101, 8491-8496.
98. Nathan, C., and Ding, A. (2010). Nonresolving inflammation. Cell 140, 871-882.
99. Navarro-Xavier, R. A., Newson, J., Silveira, V. L. F., Farrow, S. N., Gilroy, D. W., and Bystrom, J. (2010). A new strategy for the identification of novel molecules with targeted proresolution of inflammation properties. J. Immunol. 184, 1516-1525.
100. Nigam, S., Fiore, S., Luscinskas, F. W., and Serhan,C. N. (1990). LipoxinA4 and lipoxin B4 stimulate the release but not the oxygenation of arachidonic acid in human neutrophils: dissociation between lipid remodeling and adhesion. J. Cell. Physiol. 143, 512-523.
101. Norling, L. V., Dalli, J., Flower, R. J., Serhan, C. N., and Perretti, M. (2012). Resolvin D1 limits polymorphonuclear leukocytes recruitment to inflammatory loci: receptor dependent actions. Arterioscler. Thromb. Vasc. Biol. 32, 1970-1978.
102. Norling,L.V.,Spite,M.,Yang,R.,Flower, R. J., Perretti, M., and Serhan, C. N. (2011). Cutting edge: humanized nano-proresolving medicines mimic inflammation-resolution and enhance wound healing. J. Immunol. 186, 5543-5547.
103. Ogawa, S., Urabe, D., Yokokura, Y., Arai, H., Arita, M., and Inoue, M. (2009). Total synthesis and bioactivity of resolvin E2. Org. Lett. 11,3602-3605.
104. Oh, S. F., Dona, M., Fredman, G., Krishnamoorthy, S., Irimia, D., and Serhan, C. N. (2012). Resolvin E2 formation and impact in inflammation resolution. J. Immunol. 188, 4527-4534.
105. Oh, S. F., Pillai, P. S., Recchiuti, A., Yang, R., and Serhan, C. N. (2011). Pro-resolving actions and stereoselective biosynthesis of 18S E-series resolvins in human leukocytes and murine inflammation. J. Clin. Invest. 121, 569-581.
106. Ohira, T., Arita, M., Omori, K., Recchiuti, A., Van Dyke, T. E., and Serhan,C. N. (2009). Resolvin E1 receptor activation signals phosphorylation and phagocytosis. J. Biol. Chem. 285, 3451-3461.
107. O'Neill, L. A., Sheedy, F. J., and McCoy, C. E. (2011). MicroRNAs: the finetuners of Toll-like receptor signalling. Nat. Rev. Immunol. 11, 163-175.
108. Papayianni, A., Serhan, C. N., Phillips, M. L., Rennke, H. G., and Brady, H. R. (1995). Transcellular biosynthesis of lipoxin A4 during adhesion of platelets and neutrophils in experimental immune complex glomerulonephritis. Kidney Int. 47, 1295-1302.
109. Park, C. K., Lü, N., Xu, Z. Z., Liu, T., Serhan, C. N., and Ji, R. R. (2011). Resolving TRPV1 and TNF(α-mediated spinal cord synaptic plasticity and inflammatory pain with neuroprotectin D1. J. Neurosci. 31, 15072-15085.
110. Perretti, M., Chiang, N., La, M., Fierro, I. M., Marullo, S., Getting, S. J., Solito, E., and Serhan, C. N. (2002). Endogenous lipidand peptidederived anti-inflammatory pathways generated with glucocorticoid and aspirintreatmentactivatethelipoxin A4 receptor. Nat. Med. 8,1296-1302.
111. Perretti, M.,and Dalli, J.(2009). Exploiting the annexin A1 pathway for the development of novel antiinflammatory therapeutics. Br. J. Pharmacol. 158, 936-946.
112. Psychogios, N., Hau, D. D., Peng, J., Guo, A. C., Mandal, R., Bouatra, S., Sinelnikov, I., Krishnamurthy, R., Eisner, R., Gautam, B., Young, N., Xia, J., Knox, C., Dong, E., Huang, P., Hollander, Z., Pedersen, T. L., Smith, S. R., Bamforth, F., Greiner, R., McManus, B., Newman, J. W., Goodfriend, T., and Wishart, D. S. (2011). The human serum metabolome. PLoS ONE 6, e16957. doi:10.1371/journal.pone.0016957
113. Radmark, O., Werz, O., Steinhilber, D., and Samuelsson, B. (2007). 5Lipoxygenase: regulation of expression and enzyme activity. Trends Biochem. Sci. 32, 332-341.
114. Rajasagi, N. K., Reddy, P. B. J., Suryawanshi, A., Mulik, S., Gjorstrup, P., and Rouse, B. T. (2011). Controlling herpes simplex virus-induced ocular inflammatory lesions with the lipid-derived mediator resolvin E1. J. Immunol. 186, 1735-1746.
115. Recchiuti, A., Krishnamoorthy, S., Fredman, G., Chiang, N., and Serhan, C. N. (2011). MicroRNAs in resolution of acute inflammation: identification of novel resolvin D1-miRNA circuits. FASEB J. 25, 544-560.
116. Reville,K.,Crean,J. K.,Vivers,S.,Dransfield, I., and Godson, C. (2006). Lipoxin A4 redistributes myosin IIA and Cdc42 in macrophages: implications for phagocytosis of apoptotic leukocytes. J. Immunol. 176, 1878-1888.
117. Romano, M. (2010). Lipoxin and aspirin-triggered lipoxins. Scientific World Journal 10, 1048-1064.
118. Romano, M., and Serhan, C. N. (1992). Lipoxin generation by permeabilized human platelets. Biochemistry 31, 8269-8277.
119. Samuelsson, B. (1983). Leukotrienes: mediators of immediate hypersensitivity reactions and inflammation. Science 220, 568-575.
120. Samuelsson, B. (2012). Role of basic science in the development of new medicines: examples from the eicosanoid field. J. Biol. Chem. 287, 10070-10080.
121. Samuelsson, B., Dahlen, S. E., Lindgren, J. A., Rouzer, C. A., and Serhan, C. N. (1987). Leukotrienes and lipoxins: structures, biosynthesis, and biological effects. Science 237, 1171-1176.
122. Scalia, R., Gefen, J., Petasis, N. A., Serhan, C. N., and Lefer, A. M. (1997). Lipoxin A4 stable analogs inhibit leukocyte rolling and adherence in the rat mesenteric microvasculature: role of P-selectin. Proc. Natl. Acad. Sci. U.S.A. 94, 9967-9972.
123. Schwab, J. M., Chiang, N., Arita, M., and Serhan, C. N. (2007). Resolvin E1 and protectin D1 activate inflammation-resolution programmes. Nature 447, 869-874.
124. Serhan, C. N. (2004). A search for endogenous mechanisms of antiinflammation uncovers novel chemical mediators: missing links to resolution. Histochem. Cell Biol. 122, 305-321.
125. Serhan, C. N., Brain, S. D., Buckley, C. D., Gilroy, D. W., Haslett, C., O'Neill, L. A., Perretti, M., Rossi, A. G., and Wallace, J. L. (2007). Resolution of inflammation: state of the art, definitions and terms. FASEB J. 21, 325-332.
126. Serhan, C. N., and Chiang, N. (2008). Endogenous pro-resolving and antiinflammatory lipid mediators: a new pharmacologic genus. Br. J. Pharmacol. 153(Suppl. 1), S200-S215.
127. Serhan, C. N., Clish, C. B., Brannon, J., Colgan, S. P., Chiang, N., and Gronert, K. (2000a). Novel functional sets of lipid-derived mediators with antiinflammatory actions generated from omega-3 fatty acids via cyclooxygenase 2-nonsteroidal antiinflammatory drugs and transcellular processing. J. Exp. Med. 192, 1197-1204.
128. Serhan, C. N., Clish, C. B., Brannon, J., Colgan, S. P., Gronert, K., and Chiang, N. (2000b). Antimicroinflammatory lipid signals generated from dietary N-3 fatty acids via cyclooxygenase-2 and transcellular processing: a novel mechanism for NSAID and N-3 PUFA therapeutic actions. J. Physiol. Pharmacol. 51, 643-654.
129. Serhan, C. N., Dalli, J., Karamnov, S., Choi, A., Park, C. K., Xu, Z. Z., Ji, R. R., Zhu, M., and Petasis, N. A. (2012). Macrophage pro-resolving mediator maresin 1 stimulates tissue regeneration and controls pain. FASEB J. 26, 1755-1765.
130. Serhan, C. N., Gotlinger, K., Hong, S., Lu, Y., Siegelman, J., Baer, T., Yang, R., Colgan, S. P., and Petasis, N. A. (2006). Anti-inflammatory actions of neuroprotectin D1/protectin D1 and its natural stereoisomers:assignments of dihydroxy-containing docosatrienes. J. Immunol. 176, 1848-1859.
131. Serhan, C. N. (Guest ed.). (2005). Lipoxins and aspirin-triggered lipoxins. Prostaglandins Leukot. Essent. Fatty Acids 73, 139-321. (special issue).
132. Serhan, C. N., Haeggstrom, J. Z., and Leslie, C. C. (1996). Lipid mediator networks in cell signaling: update and impact of cytokines. FASEB J. 10, 1147-1158.
133. Serhan, C. N., Hamberg, M., and Samuelsson, B. (1984a). Lipoxins: novel series of biologically active compounds formed from arachidonic acid in human leukocytes. Proc. Natl. Acad. Sci. U.S.A. 81, 5335-5339.
134. Serhan, C. N., Hamberg, M., and Samuelsson, B. (1984b). Trihydroxytetraenes: a novel series of compounds formed from arachidonic acid in human leukocytes. Biochem. Biophys. Res. Commun. 118, 943-949.
135. Serhan, C. N., Hong, S., Gronert, K., Colgan, S. P., Devchand, P. R., Mirick, G., and Moussignac, R.-L. (2002). Resolvins: a family of bioactive products of omega3 fatty acid transformation circuits initiated by aspirin treatment that counter proinflammation signals. J. Exp. Med. 196, 1025-1037.
136. Serhan, C. N., Jain, A., Marleau, S., Clish, C., Kantarci, A., Behbehani, B., Colgan, S. P., Stahl, G. L., Merched, A., Petasis, N. A., Chan, L., and Van Dyke, T. E. (2003). Reduced inflammation and tissue damage in transgenic rabbits overexpressing 15-lipoxygenase and endogenous anti-inflammatory lipid mediators. J. Immunol. 171, 6856-6865.
137. Serhan, C. N., Maddox, J. F., Petasis, N. A., Akritopoulou-Zanze, I., Papayianni, A., Brady, H. R., Colgan, S. P.,andMadara,J. L. (1995). Design of lipoxin A4 stable analogs that block transmigration and adhesion of human neutrophils. Biochemistry 34, 14609-14615.
138. Serhan, C. N., and Petasis, N. A. (2011). Resolvins and protectins in inflammation-resolution. Chem. Rev. 111, 5922-5943.
139. Serhan, C. N., and Savill, J. (2005). Resolution of inflammation: the beginning programs the end. Nat. Immunol. 6, 1191-1197.
140. Serhan, C. N., and Sheppard, K. A. (1990). Lipoxin formation during human neutrophil-platelet interactions. Evidence for the transformation of leukotriene A4 by platelet 12lipoxygenase in vitro. J. Clin. Invest. 85, 772-780.
141. Serhan, C. N., Yang, R., Martinod, K., Kasuga, K., Pillai, P. S., Porter, T. F., Oh, S. F., and Spite, M. (2009). Maresins: novel macrophage mediators with potent antiinflammatory and proresolving actions. J. Exp. Med. 206, 15-23.
142. Sheedy, F. J., and O'Neill, L. A. J. (2008). Adding fuel to fire: microRNAs as a new class of mediators of inflammation. Ann. Rheum. Dis. 67(Suppl. 3), 50-55.
143. Sheedy, F. J., Palsson-McDermott, E., Hennessy, E. J., Martin, C., O'Leary, J. J., Ruan, Q., Johnson, D. S., Chen, Y., and O'Neill, L. A. (2010). Negative regulation of TLR4 via targeting of the proinflammatory tumor suppressor PDCD4 by the microRNA miR-21. Nat. Immunol. 11, 141-147.
144. Simiele, F., Recchiuti, A., Mattoscio, D., De Luca, A., Cianci, E., Franchi, S., Gatta, V., Parolari, A., Werba, J. P., Camera, M., Favoloro, B., and Romano, M. (2012). Transcriptional regulation of the human FPR2/ALX gene: evidence of a heritable genetic variant that impairs promoter activity. FASEB J. 26, 1323-1333.
145. Spite, M., Norling, L. V., Summers, L., Yang, R., Cooper, D., Petasis, N. A., Flower, R. J., Perretti, M., and Serhan, C. N. (2009a). Resolvin D2 is a potent regulator of leukocytes and controls microbial sepsis. Nature 461, 1287-1291.
146. Spite, M., Summers, L., Porter, T. F., Srivastava, S., Bhatnagar, A., and Serhan, C. N. (2009b). Resolvin D1 controls inflammation initiated by glutathione-lipid conjugates formed during oxidative stress. Br. J. Pharmacol. 158, 1062-1073.
147. Spite, M., and Serhan, C. N. (2011). Lipid signatures of unstable atheromas: fossils or a step toward personalized lipidomicsmetabolomics? Circ. Cardiovasc. Genet. 4, 215-217.
148. Stein, C., Clark, J. D., Oh, U., Vasko, M. R., Wilcox, G. L., Overland, A. C., Vanderah, T. W., and Spencer, R. H.(2009).Peripheralmechanismsof pain and analgesia. Brain Res. Rev. 60, 90-113.
149. Sun, Y.-P., Oh, S. F., Uddin, J., Yang, R., Gotlinger, K., Campbell, E., Colgan, S. P., Petasis, N. A., and Serhan, C. N. (2007). Resolvin D1 and its aspirin-triggered 17R epimer. Stereochemical assignments, anti-inflammatory properties, and enzymatic inactivation. J. Biol. Chem. 282, 9323-9334.
150. Svensson, C. I., Zattoni, M., and Serhan, C. N. (2007). Lipoxins and aspirintriggered lipoxin inhibit inflammatory pain processing. J. Exp. Med. 204, 245-252.
151. Takano, T., Clish, C. B., Gronert, K., Petasis, N., and Serhan, C. N. (1998). Neutrophil-mediated changes in vascular permeability are inhibited by topical application of aspirintriggered 15-epi-lipoxin A4 and novel lipoxin B4 stable analogues. J. Clin. Invest. 101, 819-826.
152. Takano,T.,Fiore,S.,Maddox,J. F.,Brady, H. R., Petasis, N. A., and Serhan, C. N. (1997). Aspirin-triggered 15-epilipoxin A4 (LXA4) and LXA4 stable analogues are potent inhibitors of acute inflammation: evidence for anti-inflammatory receptors. J. Exp. Med. 185, 1693-1704.
153. Titos, E., Rius, B., González-Périz, A., López-Vicario, C., Morán-Salvador, E., Martínez-Clemente, M., Arroyo, V., and Clária, J. (2011). Resolvin D1 and its precursor docosahexaenoic acid promote resolution of adipose tissue inflammation by elicitying macrophage polarization toward a pro-resolving phenotype. J. Immunol. 187, 5408-5418.
154. Tjonahen, E., Oh, S. F., Siegelman, J., Elangovan, S., Percarpio, K. B., Hong,S.,Arita,M.,and Serhan,C. N. (2006). Resolvin E2: identification and anti-inflammatory actions: pivotal role of human 5-lipoxygenase in resolvin E series biosynthesis. Chem. Biol. 13, 1193-1202.
155. Tobin, D. M., Roca, F. J., Oh, S. F., McFarland, R., Vickery, T. W., Ray, J. P., Ko, D. C., Zou, Y., Bang, N. D., Chau, T. T., Vary, J. C., Hawn, T. R., Dunstan, S. J., Farrar, J. J., Thwaites, G. E., King, M. C., Serhan, C. N., and Ramakrishnan, L. (2012). Host genotype-specific therapies can optimize the inflammatory response to mycobacterial infections. Cell 148, 434-446.
156. von Euler, U. S. (1973). The First Heymans Memorial Lecture, Ghent, March 24, 1972. Some aspects of the actions of prostaglandins. Arch. Int. Pharmacodyn. Ther. (Suppl), Apr, 295-307.
157. Wang, B., Gong, X., Wan, J. Y., Zhang, L., Zhang, Z., Li, H. Z., and Min, S. (2011). Resolvin D1 protects mice from LPS-induced acute lung injury. Pulm. Pharmacol. Ther. 24, 434-441.
158. Winyard, P. G., and Willoughby, D. A. (eds). (2003). Inflammation Protocols. Totowa, NJ: Humana.
159. Wittamer, V., Franssen, J. D., Vulcano, M., Mirjolet, J. F., Le Poul, E., Migeotte, I., Brezillon, S., Tyldesley, R., Blanpain, C., Detheux, M., Mantovani, A., Sozzani, S., Vassart, G., Parmentier, M., and Communi, D. (2003). Specific recruitment of antigen-presenting cells by chemerin, a novel processed ligand from human inflammatory fluids. J. Exp. Med. 198, 977-985.
160. Xu, Z.-Z., Zhang, L., Liu, T., Park, J.-Y., Berta, T.,Yang, R., Serhan, C. N., and Ji, R.-R. (2010). Resolvins RvE1 and RvD1 attenuate inflammatory pain via central and peripheral actions. Nat. Med. 16, 592-597.
161. Ye, R. D., Boulay, F., Wang, J. M., Dahlgren,C.,Gerard,C.,Parmentier, M., Serhan, C. N., and Murphy, P. M. (2009). International Union of Basic and Clinical Pharmacology. LXXIII. Nomenclature for the formyl peptide receptor (FPR) family. Pharmacol. Rev. 61, 119-161.
162. Zhao, Y., Calon, F., Julien, C., Winkler, J. W., Petasis, N. A., Lukiw, W. J., and Bazan, N. G. (2011). Docosahexaenoic acid-derived neuroprotectin D1 induces neuronal survival via secretaseand PPARgamma-mediated mechanisms in Alzheimer's disease models. PLoS ONE 6, e15816. doi:10.1371/journal.pone.0015816
163. Zhou, M., Chen, B., Sun, H., Deng, Z., Andersson, R., and Zhang, Q. (2011). The protective effects of lipoxin A4 during the early phase of severe aute pancreatitis in rats. Scand. J. Gastroenterol. 46, 211-219.